Core Viewpoint - Eli Lilly's next-generation weight loss drug retatrutide has shown the strongest weight loss results to date in its latest Phase III trial, significantly alleviating knee osteoarthritis pain and opening a promising start for upcoming research sequences [4][6]. Group 1: Weight Loss Efficacy - In the highest dose group of the trial, participants achieved an average weight loss of 23.7% over 68 weeks, with those adhering to treatment losing an average of 28.7% [4]. - The trial results indicate that retatrutide's weight loss effects are comparable to those of weight loss surgery, particularly targeting patients with a BMI of 35 or above, with 84% of participants classified as severely obese [6]. Group 2: Pain Relief and Safety - The study found that retatrutide reduced knee osteoarthritis pain by an average of 62.6%, with over 12.5% of patients reporting complete pain relief by the end of treatment [7]. - Approximately 18% of patients in the highest dose group discontinued treatment due to adverse reactions, compared to 4% in the placebo group, with the discontinuation rate closely linked to initial BMI [7]. Group 3: Competitive Landscape - Retatrutide, known as a "Triple G" drug, simultaneously mimics GLP-1, GIP, and glucagon, providing stronger appetite suppression and satisfaction compared to competitors like Novo Nordisk's semaglutide, which only targets GLP-1 [8]. - In response to retatrutide's promising data, Novo Nordisk has invested up to $2 billion to acquire global rights to an early-stage triple hormone candidate from a Chinese pharmaceutical company, aiming to catch up with retatrutide's development timeline [8]. Group 4: Future Outlook - Eli Lilly anticipates releasing results from seven additional Phase III trials by the end of 2026, which may yield even higher efficacy data specifically designed for weight loss [7]. - The global market for obesity and diabetes medications is expected to exceed $100 billion by the 2030s, indicating significant growth potential in this sector [6].

整理 | GLP1减重宝典内容团队 最近在多个社交平台和网购平台，名为"转运蛋白""暴瘦王"的减肥产品，被包装成网红爆款，吸引了大量消费者。然而，有消费者反 映，使用了这样的减肥产品，却险些丧命。到底发生了什么呢？近期，央视新闻《每周质量报告》记者对此进行了调查。 ▍注射减肥针第4天送医抢救 回想起死里逃生的经历，江苏苏州的陈女士至今仍心有余悸。一个多月前，她从一位发小的朋友圈里看到了一款名为"四点暴瘦 王"的"减肥针"广告。朋友承诺，打一针至少瘦7斤。陈女士很是动心，便花了900块钱买了一个疗程的产品，总共三针。 因为从没用过这种产品，为求稳妥，陈女士特意将推荐剂量减了一半才敢注射。注射之后，陈女士出现了呕吐、反胃、厌食等反应， 但她并未在意，认为这是正常的药物反应，"我确实是头三天几乎一天瘦2斤，4天瘦了10斤。" 陈女士注射减肥针的第4天，身体状况急转直下，"第四天开始吐东西，吐绿色的、黄色的，去医院的时候，人家告诉我那是胆汁。当 时我的脉不跳了，包括后面抽血、抢救、做房颤一系列的东西，我都是不知道的，醒了，我男朋友告诉我说，你差一点就要下病危通 知书了。" 经过抢救，陈女士转危为安。出院时，医生嘱咐她 ...

整理 | GLP1减重宝典内容团队 司美格鲁肽原研由诺和诺德开发，已在全球获批用于2型糖尿病、肥胖、心血管事件风险管理以及慢性肾病。今年前三季度，该产品在 全球实现约255亿美元销售额，是目前最成功的GLP-1药物之一。 2025年12月11日，CDE官网信息显示，正大天晴旗下连云港润众制药的司美格鲁肽注射液递交上市申请，注册分类为3.3类，这意味着 该产品正式进入上市冲刺阶段。 正大天晴的司美格鲁肽于2023年6月首次申报临床，同年8月获批开展，10月即启动试验，推进速度明显快于行业平均水平。目前，该 产品已开展两项Ⅲ期关键临床： 一是用于治疗2型糖尿病的适应症，于2024年1月启动，今年6月已完成整个试验； 二是用于肥胖管理的适应症，于2024年12月启动，并在今年8月完成全部患者招募。 | 受理品种目录浏览 | | 在审品种目录浏览 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 年 年 | 2025 | | ▼ 药品类型: | 美部 | V 申请类型: | ま部 | V | | | 플랜드: | 请输入受理 ...

号称打一针至少瘦7斤，江苏的陈女士看到"减肥针"广告后，十分心动。陈女士注射后，出现了呕吐、反胃、厌食等反应，"第四天开始 吐东西，吐绿色的、黄色的，医生告诉我那是胆汁，我已经把我的胃黏膜烧没了，躺着仰着脸的时候，就开始吐血了……" 整理 | GLP1减重宝典内容团队 浙江湖州的沈女士，在美容院注射了号称"打一针瘦10斤"的"减肥 针"。注射后第2天，沈女士就出现不适，第3天开始发烧，第4天病情急剧恶化陷入昏迷，被紧急送往ICU抢救。她在医院治疗了4个多 月，总算捡回一条命。但私自注射来源不明的"减肥针"造成了肝肾功能衰竭，现在每3个月就要复查血和肝肾功能。 记者调查发现，"四点暴瘦王""黑金转运蛋白"等网红"减肥针"通过盗用、借用生产资质去备案，实则都是"三无产品"。犯罪分子在小作 坊里，用化妆品的制作工艺去生产药品，把非法购买来的司美格鲁肽原料包装成带有"减肥神药"光环的减肥针剂，最终流向了美容院、 小诊所等地方。经过夸大其词的营销，生产成本仅为4元的减肥针剂，摇身一变，价格瞬间飙升几十倍甚至百倍。 *本文仅供医疗卫生专业人士参考 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文 ...

整理 | GLP1减重宝典内容团队 ▍ 青少年肥胖是一个大问题 "2022 年 12 月 23 日，诺和诺德宣布，已于美国食品药品监督管理局 (FDA) 已批准 司美格鲁肽成为第一个也是目前唯一一个抗肥 胖青少年药物 。 " 全球青少年肥胖率持续增加：根据世界卫生组织的数据，全球青少年肥胖率自1975年以来增加了10倍。截至2016年，全球超过1.24 亿儿童和青少年患有肥胖症。 中国青少年肥胖率高居亚洲前列：根据《中国儿童体质发展报告（2010-2019）》，2019年中国青少年肥胖率为18.3%，高于亚洲其 他国家。 青少年肥胖与长期健康问题有关：青少年肥胖可能会导致多种健康问题，如高血压、高胆固醇、糖尿病、骨关节问题和心理健康问 题等。 尤其是近年来，随着城市化和现代化的加速，青少年的生活方式趋向于缺乏运动、不良饮食和长时间使用电子产品等不良习 惯，这些是青少年肥胖的原因之一。 ▍ 从成人肥胖症到青少年 司美格鲁肽是一种 GLP-1 受体激动剂，是自 2014 年以来首个获批用于患有一般性肥胖或超重的成人进行慢性体重管理的药物。 司 美格鲁肽适用于慢性体重管理及至少有一种与体重相关的并发症，例如 2 型 ...

Core Viewpoint - The article discusses the latest clinical results of GLP-1 oral weight loss drug ASC30 by Gilead Sciences, highlighting its competitive position in the oral weight loss drug market and comparing it with other leading products [5][6][7]. Summary by Sections Clinical Results of ASC30 - Gilead Sciences announced that ASC30 achieved a weight loss of 7.7% at the highest dose in a Phase II study involving 125 participants with obesity or overweight and at least one weight-related comorbidity [5]. - The study evaluated three dosing regimens (20mg, 40mg, and 60mg) with average weight loss of 5.4%, 7%, and 7.7% respectively, all statistically significant [5]. - No plateau in weight loss was observed during the trial period [5]. Comparison with Competitors - Gilead's data positions ASC30 in the upper-middle range of performance among oral weight loss drugs, with intense competition in the market [5]. - Novo Nordisk is awaiting FDA approval for its oral version of Wegovy, which demonstrated a weight loss of 15.1% over 68 weeks at a 50mg daily dose [5]. - Eli Lilly's orforglipron achieved a 12.4% weight loss over 72 weeks, but analysts noted persistent gastrointestinal side effects [6]. Safety and Tolerability - Gilead reported that the incidence of vomiting with ASC30 was about half that of orforglipron, with all gastrointestinal adverse events classified as grade 1-2 and occurring mainly during the dose escalation phase [7]. - No grade 3 or more severe events were reported, nor any serious drug-related adverse events [7]. - The CEO of Gilead indicated that ASC30 shows potential best-in-class characteristics in terms of weight loss efficacy and gastrointestinal tolerability [7]. Strategic Focus - Gilead plans to submit data to the FDA and apply for a Phase II end-of-study meeting in Q1 2026, having shifted its strategic focus to metabolic diseases earlier this year [7]. - Other competitors in the oral weight loss drug space include Viking Therapeutics, which reported a maximum weight loss of 12.2% in a Phase II study, but faced a 38% dropout rate among participants at the most effective dose [7].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 你有没有注意到，冬天似乎更容易变瘦，而到了夏天体重却容易增加？其实，这种现象并非你的错觉！近期，丹麦哥本哈根大学联合瑞典卡罗 林斯卡学院的研究团队发现，季节性的光照时长变化会通过调控进食规律，从而影响人体的能量代谢与脂肪储存。 这项刊登在《Cell Metabolism》的最新成果，让我们看到了无需节食或锻炼也能瘦身的"天然减重新思路"。 一、光照如何成为"隐形减脂教练" 短日照：激活身体的"燃脂开关" 在实验中，科学家们将小鼠分为三组，分别模拟夏季（18小时光照）、冬季（6小时光照）和赤道（12小时光照）的环境。经过13周观察，发 现冬季短日照组（SL）的小鼠体重和脂肪量明显低于另外两组，尤其是高脂饮食的小鼠，脂肪堆积减少最为显著，肝脏中的甘油三酯含量也 下降了约20%。 更令人惊喜的是，短日照组小鼠的能量消耗（EE）呈上升趋势（p=0.061）。这就像身 ...

Core Insights - The article discusses the impact of seasonal light exposure on body weight regulation, highlighting that shorter daylight in winter can lead to weight loss and fat reduction due to changes in energy metabolism and eating patterns [6][11]. Group 1: Mechanisms of Light Exposure on Weight Management - Short daylight activates the body's "fat-burning switch," leading to lower body weight and fat mass in mice exposed to winter-like conditions, with a significant reduction in liver triglyceride levels by approximately 20% [11]. - The study indicates that light exposure influences eating rhythms, where mice in long daylight conditions exhibit disrupted lipid metabolism, while those in short daylight conditions have enhanced fat oxidation and reduced fat synthesis [12]. - Contrary to previous beliefs, melatonin was found not to be the key regulator of seasonal metabolism, as the fat-reducing effects of short daylight persisted even in the absence of melatonin [13]. Group 2: Scientific Evidence Supporting Light-Related Fat Loss - Short daylight alters the circadian rhythms of metabolic genes in peripheral tissues, delaying the peak expression of lipid metabolism-related genes by about 4 hours, which affects fat synthesis and breakdown [14]. - Mice in short daylight conditions showed a higher respiratory exchange ratio (RER), indicating increased carbohydrate utilization and enhanced fat oxidation, with a rhythmic increase in non-esterified fatty acids (NEFA) in the plasma [15]. - Time-restricted feeding (TRF) mimicking short daylight conditions resulted in similar metabolic indicators as those observed in short daylight mice, suggesting that limiting eating times can effectively simulate the fat loss benefits of reduced light exposure [16].

整理 | GLP1减重宝典内容团队 ▍ 癌症和肥胖之间确实存在一定的关联，随着肥胖率的上升，一些癌症的发病率也在增加 和肥胖有直接关系的癌症种类包括结直肠癌、肝癌、胆囊癌、胰腺癌、乳腺癌、子宫癌、卵巢癌、肾癌、甲状腺癌、多发性骨髓瘤、 胃贲门癌和食管腺癌 等至少12种。 肥胖被认为是这些癌症的致病因素 ，随着肥胖率的上升，这些癌症的发病率也在增加。研究表明，肥胖相关的癌症在年轻人中的发病 率增长尤为显著，这提示了改善公共卫生政策和生活方式的重要性，以应对肥胖和相关癌症发病率的上升趋势。 点击关注，追踪最新GLP-1资讯 ▍ 肥胖与癌症风险之间的关系通常涉及以下几个机制： 慢性炎症 ：肥胖可以引起全身范围内的慢性炎症，这种炎症状态与癌症的发生和发展有关。 代谢紊乱 ：肥胖导致的代谢紊乱，如胰岛素抵抗和性激素水平的变化，可能促进肿瘤细胞的生长和发展。 肿瘤微环境的改变 ：肥胖会影响肿瘤微环境，改变肿瘤细胞与免疫细胞的相互作用，促进肿瘤生长。 免疫功能的抑制 ：肥胖可能会降低肿瘤内重要免疫细胞CD8+T细胞的数量和活性，从而抑制抗肿瘤免疫监视。 肿瘤相关巨噬细胞的作用 ：肥胖相关的炎性细胞因子会促进肿瘤相关巨噬细胞 ...

Core Insights - Structure Therapeutics announced positive results from its oral GLP-1 receptor agonist aleniglipron in the ACCESS clinical trial, showing significant weight loss in overweight and obese adults with related complications [4][6] - The ACCESS II study demonstrated a maximum placebo-adjusted average weight loss of 15.3% with a 240mg dose, indicating the drug's tolerability aligns with GLP-1 class characteristics [6] - The company plans to engage with the FDA for a Type B meeting in the first half of next year to finalize the Phase III study protocol [6] Group 1: Clinical Trial Results - In the core IIb ACCESS study, participants receiving 120mg of aleniglipron achieved an average weight loss of 11.3% after 36 weeks, with a 10.4% rate of treatment discontinuation due to adverse events [4] - Among the 120mg group, 86% of participants lost at least 5% of their body weight, and 70% achieved over 10% weight loss [4] - The ACCESS open-label extension results indicated sustained weight loss up to 44 weeks, with improved tolerability when starting at a lower 2.5mg dose [6] Group 2: Safety and Tolerability - No drug-related liver injury, persistent liver enzyme elevation, or QTc prolongation was observed across all studies [6] - An exploratory study with a lower starting dose of 2.5mg showed improved tolerability without any treatment discontinuation due to adverse events during the initial dosing phase [6] Group 3: Future Plans and Market Potential - CEO Raymond Stevens highlighted that the latest results demonstrate aleniglipron's differentiated characteristics, offering clinically meaningful and competitive weight loss with safety suitable for chronic treatment [6] - The drug presents new treatment hope for millions of patients struggling with obesity and related complications [6]